Active, not recruitingPhase 2NCT06899217

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Studying Idiopathic gastroparesis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: CinDome Pharma, Inc.
Intervention: CIN-102 Dose 15mg(drug)
Enrollment: 416 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (30)

Gastro Health - Birmingham, Birmingham, Alabama, United States
G & L Research, LLC, Foley, Alabama, United States
The Center for Clinical Trials, Saraland, Alabama, United States
Del Sol Research Management, LLC, Tucson, Arizona, United States
Applied Research Center of Arkansas, Inc, Little Rock, Arkansas, United States
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
Hope Clinical Research LLC, Canoga Park, California, United States
Erick H. Alayo Medical Corporation, Chula Vista, California, United States
Flourish Research - Los Angeles (Covina), Covina, California, United States
Gastro Care Institute, Lancaster, California, United States
Downtown L.A. Research Center, Inc., Los Angeles, California, United States
Acclaim Clinical Research, San Diego, California, United States
Focus Clinical Research - West Hills, West Hills, California, United States
University of Colorado Anschutz, Aurora, Colorado, United States
Rocky Mountain Gastroenterology (RMG), Lakewood, Colorado, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06899217 on ClinicalTrials.gov

Other trials for Idiopathic gastroparesis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic gastroparesis →

← Back to all trials